I'm LongbridgeAI, I can summarize articles.Bone Biologics extended the validated shelf life of rhNELL-1 to 32 months, enhancing manufacturing and supply chain flexibility. This update supports the advancement of its NB1 spine fusion trial, a multicenter randomized pilot study in Australia targeting up to 30 patients with degenerative disc disease undergoing lumbar interbody fusion. The NB1 therapy combines rhNELL-1 with demineralized bone matrix for controlled bone regeneration. Enrollment is currently progressing.
- Bone Biologics extended validated shelf life for rhNELL-1 to 32 months, supporting supply readiness as its NB1 trial advances. * No clinical results were presented; the update positions the program for pivotal-study scale manufacturing. * Management framed the outcome as improved flexibility for manufacturing, storage, distribution planning, inventory control, lot sizing. * NB1 combines rhNELL-1 with demineralized bone matrix, targeting controlled bone regeneration in spine fusion procedures. * The multicenter randomized pilot study in Australia targets up to 30 degenerative disc disease patients undergoing lumbar interbody fusion; enrollment is progressing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bone Biologics Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608120800PRIMZONEFULLFEED9808238) on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)